An Open-Label, Uncontrolled, Phase II Trial Evaluating the Single-Dose and Steady-State Pharmacokinetics of EndoTAG [paclitaxel] and Its Effect on the Blood Supply and the Angiogenesis of Hepatic Metastases in Patients With a Carcinomatous Primary Tumor Other Than Hepatocellular (HCC), Biliary or Bile Duct Carcinoma.

Trial Profile

An Open-Label, Uncontrolled, Phase II Trial Evaluating the Single-Dose and Steady-State Pharmacokinetics of EndoTAG [paclitaxel] and Its Effect on the Blood Supply and the Angiogenesis of Hepatic Metastases in Patients With a Carcinomatous Primary Tumor Other Than Hepatocellular (HCC), Biliary or Bile Duct Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Apr 2012

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Cancer metastases
  • Focus Pharmacokinetics
  • Sponsors MediGene Inc
  • Most Recent Events

    • 18 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Nov 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
    • 10 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top